Monsanto Company
Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment
Published in Medical Letter on the CDC and FDA, March 29th, 2009
Monsanto's historic investment in research and development in breeding and biotechnology has contributed to a 24 percent compound annual growth rate for the company's Seeds and Genomics segment since 2001. This is one of the key messages Kerry Preete, Monsanto's Vice President of International Commercial, will tell investors today as part of a presentation at the Credit Suisse 14th Annual Global Ag Productivity Conference in London.
"Our R&D investment in technology has allowed us to build a robust pipeline of game-changing products focused on yield and stress," Preete will say. "We continue to be the leading company delivering innovations to farmers that help them...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- BioMed Central
Inadequacy of current guidelines for sexually transmitted infections - New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Drug blocks 2 of world's deadliest emerging viruses - Anesthesia
American Society of Anesthesiologists (ASA) - Myths About 'Never Ending Pursuit of Patient Safety and Satisfaction' Debunked - Baxter International Inc.
FDA Classifies Recent Urgent Device Correction on Baxter’s COLLEAGUE Infusion Pump as a Class I Recall - CytoDyn, Inc.
CytoDyn Responds to FDA as High Court Rules Agency Cannot Guarantee Drug Safety - Life Sciences
Recent findings in life sciences described by researchers from Harvard University, Medical Department - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
